Appropriate management of axial spondyloarthritis

Current Rheumatology Reports

Volumn 9, Issue 5, 2007, Pages 375-382

  LaSalle, Sean P ^b   Deodhar, Atul A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; SALAZOSULFAPYRIDINE; THALIDOMIDE;

ANKYLOSING SPONDYLITIS; AXILLA; BONE DEVELOPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENTHESITIS; HIP ARTHROPLASTY; HUMAN; OSSIFICATION; OSTEOPOROSIS; PAIN ASSESSMENT; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SPINE MOBILITY; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; PHYSICAL THERAPY MODALITIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348982966     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0060-8     Document Type: Review

References (49)

1. Khan MA: Update on spondyloarthropathies. Ann Intern Med 2002, 136:896-907.
2. Zochling J, Braun J, van der Heijde D: Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006, 20:521-537. An excellent review of core sets of health domains used for monitoring AS in clinical practice and clinical trials. Discusses measures for assessing disease activity, functional status, and structural damage.
3. Anderson JJ, Baron G, van der Heijde D, et al.: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
4. Calin A, Garrett SL, Whitelock HC, et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
5. Garrett SL, Jenkinson T, Kennedy LG, et al.: New approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 1994, 21:2286-2291.
6. Barlow JH, Barefoot J: Group education for people with arthritis. Pt Educat Counsel 1996, 27:257-267.
7. Dagfinrud H, Hagen K, Kvien TK: Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2006, (4):CD002822.
8. van Tubergen A, Landewe R, van der Heijde D, et al.: Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2001, 45:430-438.
9. Zochling J, van der Heijde D, Burgos-Vargas R, et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006, 65:442-452. The authors present 10 key evidence-based recommendations for the treatment of AS using a systematic literature search and categorizing the evidence.
10. van der Heijde D, Dijkmans B, Geusens P, et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. The phase 3 ASSERT trial confirmed the safety and efficacy of infliximab in treating AS.
11. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356.
12. van der Heijde D, Kivitz A, Schiff M, et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 2006, 54:2136-2146. The phase 3 ATLAS trial is the largest trial to date showing the safety and efficacy of adalimumab in the treatment of AS. This is also the first trial showing benefit in patients with complete spinal ankylosis.
13. Chen J, Liu C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005, (2):CD004800.
14. Dougados M, van der Linden SM, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
15. Chen J, Liu C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004, (3):CD004524.
16. van Denderen JC, van der Paardt M, Nurmohamed MT, et al.: Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005, 64:1761-1764.
17. Miceli-Richard C, Dougados M: NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002, 20:S65-S66.
18. van der Heijde D, Baraf H, Ramos-Remus C, et al.: Evaluation of the efficacy of etoricoxib in ankylosing spondylitis. Arthritis Rheum 2005, 52:1205-1215.
19. Luukkainen R, Nissila M, Asikainen E, et al.: Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondyloarthropathy. Clin and Exp Rheumatol 1999, 17:88-90.
20. Karabacakoglu A, Karakose S, Ozerbil OM, Odev K: Fluoroscopy-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with ankylosing spondylitis. Acta Radiol 2002, 43:425-427.
21. Peters N, Ejstrup L: Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992, 21:134-138.
22. Braun J, Zochling J, Baraliakos X, et al.: Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006, 65:1147-1153.
23. Gonzalez-Lopez L, Garcia-Gonzalez M, Vazque-Del-Mercado M, et al.: Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004, 31:1568-1574.
24. Marzo-Ortega H, McGonagle D, Jarrett S, et al.: Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005, 64:1568-1575.
25. Perez-Guijo V, Cravo A, Castro Mdel C, et al.: Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 2007, 74:254-258.
26. Maksymowych W, Jhangri GS, Fitzgerald A, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous Pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.
27. Maksymowych W, Lambert RG, Jhangri GS, et al.: Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous Pamidronate therapy. J Rheumatol 2001, 28:144-155.
28. Toussirot E, Lohse A, Le Huede G, et al.: Treatment of refractory and active spondylarthropathies with Pamidronate: an open study [abstract #SAT0026]. Presented at the European League Against Rheumatism. Berlin; June 19-24, 2004.
29. Wei JC, Chan TW, Lin HS, et al.: Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 2003, 30:2627-2631.
30. Huang F, Gu J, Zhao W, et al.: One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002, 47:249-254.
31. Haibel H, Rudwaleit M, Listing J, Sieper J: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005, 64:296-298.
32. Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
33. Braun J, Baraliakos X, Brandt J, et al.: Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005, 44:670-676.
34. Visvanathan S, Deodhar A, Braun J, et al.: Modulation of biomarkers of inflammation and bone turnover and associations with bone mineral density in ankylosing spondylitis patients treated with infliximab [abstract #Sat0317]. Presented at the European League Against Rheumatism. Amsterdam; June 21-24, 2006.
35. Davis JC Jr, van der Heijde D, Braun J, et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003, 48:3230-3236.
36. Davis JC Jr, van der Heijde D, Braun J, et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005, 64:1557-1562.
37. Spondyloarthritis Research and Treatment Network: SPARTAN Educational Slide Set. Available at http://www.spartangroup.org/. Accessed July 23, 2007.
38. Wanders A, van der Heijde D, Landewe, et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthritis Rheum 2005, 52:1756-1765. This is the only trial to date that shows a reduction in radiographic progression with an AS treatment.
39. Braun J, Landewe R, Hermann KG, et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Arthritis Rheum 2006, 54:1646-1652.
40. Braun J, Baraliakos X, Golder W, et al.: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab. Arthritis Rheum 2003, 48:1126-1136.
41. van der Heijde D: Two-year etanercept therapy does not inhibit radiographic progression in patients with AS [abstract #OP0090]. Presented at the European League Against Rheumatism. Amsterdam; June 21-24, 2006. The author reports that etanercept does not inhibit radiographic progression in AS as compared to a historic cohort.
42. van der Heijde D, Landewe R, Deodhar A, et al.: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab [abstract #OPO111]. Presented at the European League Against Rheumatism. Barcelona; June 13-16, 2007.
43. Brandt J, Listing J, Krause A, et al.: Socioeconomic consequences for patients with active ankylosing spondylitis treated for two years with infliximab in a clinical trial [abstract #FRI0201]. Presented at the European League Against Rheumatism. Lisbon; June 18-21, 2003.
44. van der Heijde D, DeVlam K, Burmester G, et al.: Infliximab improves productivity in employed patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) [abstract #SAT0044]. Presented at the European League Against Rheumatism. Berlin; June 9-12, 2004.
45. Kobelt G, Andlin-Sobocki P, Maksymowych W: The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006, 33:732-740. Using a disease model adapted to the Canadian setting, the authors show that infliximab is cost-effective in their system.
46. Sweeney S, Gupta R, Taylor G, Calin A: Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001, 28:1862-1868.
47. van Royen BJ, De Gast A: Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis 1999, 58:399-406.
48. Toussirot E, Saas P, Pouthier F, et al.: Increased levels of soluble Ctla-4 molecule in serum of patients with spondyloarthropathies [abstract #1103-362]. Presented at the American College of Rheumatology Annual Meeting. Washington, DC; November 10-15, 2006. The increased levels of CTLA-4 in the serum of patients with SpA suggests that there might be a role for abatacept therapy in SpA.
49. Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nature Med 2007, 13:156-163. New data on DKK-1 as a regulator of the Wnt pathway, known to be important in osteoblastic bone formation, may play a role in understanding the current disconnect between improvement in disease activity achieved by TNF inhibitors and their inability to prevent radiographic progression.